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INTRODUCTION
Congenital diaphragmatic hernia
(CDH) is a severe developmental anom-
aly, with a mean incidence of 1:2500 Q1
live births, in which etiology remains
poorly understood (1,2). This congenital
anomaly is characterized by a diaphrag-
matic defect that allows intra-thoracic
herniation of abdominal organs, and
consequently, maldevelopment of the
alveoli and pulmonary vessels. For
many years, this malformation was
thought to be a surgical emergence,
solely related to a diaphragmatic defect,
and potentially curable by surgical clo-
sure of this defect after birth, which al-
lowed lung expansion. However, during
90 years, CDH pathophysiology pro-
gressed for a physiological emergence
(3,4). It is now clear that lung hypoplasia
and consecutive persistent pulmonary
hypertension (PH) associated with this
disorder are the key determinants of
mortality (1–4). Despite the improve-
ments in understanding CDH patho-
physiology and advances in neonatal
care, such as the use of extra corporeal
membrane oxygenation and inhaled ni-
tric oxide, the mortality (50%) and mor-
bidity rate in CDH newborns remains
exceedingly high (1–4). In humans, CDH
can be accurately diagnosed at second
trimester during routine ultrasound ex-
amination. Therefore it is amenable to
antenatal therapies. Hence, antenatal
therapies that promote fetal lung growth
remain an appealing approach to im-
prove survival of CDH fetuses. How-
ever, fetal surgical interventions, such as
fetal tracheal occlusion, are invasive,
technically demanding, limited by the
maternal and fetal risks, and their effi-
cacy is still not determined, with contro-
versial results in survival and morbidity
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rates (5,6). Therefore, less invasive ap-
proaches such as antenatal pharmaco-
logical treatment to stimulate lung
growth before birth and to treat PH are
also under investigation (3,7–10).
The renin–angiotensin system (RAS) is
a classical endocrine system regulating
blood pressure, electrolyte and fluid ho-
meostasis, involving several key compo-
nents, namely angiotensinogen (the he-
patic-derived precursor), two critical
enzymes, renin (secreted from the juxta-
glomerular apparatus of the kidney) and
angiotensin-converting enzyme (ACE,
pulmonary-bound metalloproteinase),
whose sequential actions produce an-
giotensin I and the physiologically ac-
tive, angiotensin II (ANGII), respectively
(11). ANGII operates on two G protein-
coupled receptors, the ANGII type 1
(AT1) and type 2 (AT2) receptors (11).
During the last two decades, in addition
to this classic endocrine system, evidence
has demonstrated the presence of a local
RAS with autocrine/paracrine actions in
several developing organs, such as fetal
kidney, heart, vasculature and adrenal
development (12).
Regarding lung morphogenesis, there
is some evidence that lung expresses
ACE as well as AT1 and AT2 receptors
during fetal development (13–15). How-
ever, RAS components expression pat-
tern, as well as effects during lung mor-
phogenesis, is largely unknown.
In this study, we assessed the expres-
sion pattern and function of RAS during
fetal lung development. Moreover, we
assessed the role of RAS as a putative
target for treatment of fetal lung hy-
poplasia in CDH.
MATERIALS AND METHODS
Animal experiments were performed
according to the Portuguese law for ani-
mal welfare (16; Diário da República, Por-
taria 1005/92). Animals were housed in
an accredited mouse house and treated
as specified by the recommendations of
the Helsinki convention (17) and the
Guide for the Care and Use of Laboratory
Animals, published by the US National
Institutes of Health (18). Q6
Experimental Design and Animal
Model
In vitro studies were carried out to as-
sess expression and function of RAS in
fetal lung, whereas in vivo studies were
performed to explore RAS as a target to
treat fetal lung hypoplasia using the
 nitrofen-induced CDH rat model (19).
Sprague Dawley female rats (225 g;
Charles River; Barcelona, Spain) were
maintained in appropriate cages under
controlled conditions and fed with com-
mercial solid food. The rats were mated
and checked daily for vaginal plug. The
day of plugging was defined as gesta-
tional d 0.5 for time-dating purposes. 
According to the nitrofen-induced CDH
rat model (19), at 9.5 d postconception
(dpc), randomly selected pregnant rats
were exposed to 100 mg nitrofen (2,4-
dichlorophenyl-p-nitrophenylether). At
different time points, fetuses were har-
vested by cesarean section. After fetal de-
capitation, a toraco-laparotomy was per-
formed under a binocular surgical
microscope (Leica, Wild M651.MSD,
Heerbrugg, Switzerland) to inspect the
diaphragm and harvest the organs. Fe-
tuses were assigned to three experimen-
tal groups: (i) Control group (C), fetuses
not exposed to nitrofen; (ii) Nitrofen
group (N), fetuses exposed to nitrofen
without CDH; (iii) CDH group, fetuses
exposed to nitrofen with CDH.
In Vitro Studies
Normal fetuses removed by cesarean
section at 13.5, 15.5, 17.5, 19.5 and 21.5
dpc were killed by decapitation, and
lungs dissected and processed for im-
munohistochemistry (IHC). Lungs of fe-
tuses with 13.5 dpc were also dissected
to perform fetal lung explants cultures
and posterior western blot analysis.
IHC
IHC was performed on formalin-fixed
and paraffin-embedded lungs, as previ-
ously described by Nogueira-Silva et al.
(7). Renin antibody (sc-27320; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was
used in a 1:25 dilution, ACE antibody (sc-
20791; Santa Cruz Biotechnology Inc.) in a
1:75 dilution, angiotensinogen antibody
(Abbiotec LLC, San Diego, CA, USA) in a
1:100 dilution, AT1 receptor antibody (sc-
1173; Santa Cruz Biotechnology Inc.) in a
1:50 dilution and AT2 receptor antibody
(sc-9040; Santa Cruz Biotechnology Inc.)
in a 1:25 dilution. Incubation with the Ul-
traVision detection system anti-polyvalent
horseradish peroxidase (Lab Vision Cor-
poration, Fremont, CA, USA) or with the
goat ImmunoCruz™ Staining System
(Santa Cruz Biotechnology Inc.) was car-
ried out according to the manufacturer’s
instructions.
Fetal Lung Explant Cultures
Recombinant ANGII (Sigma, St Louis,
MO, USA), AT1-antagonist (ZD-7155;
Tocris Cookson, Bristol, UK) and AT2-an-
tagonist (PD-123319; kindly supplied by
Pfizer, Groton, CT, USA) were added
daily to lung explants to achieve increas-
ing concentrations of ANGII (from 10–9 to
10–4 mol/L) or ZD-7155 or PD-123319 at
10–5 mol/L. These doses were selected ac-
cording to the literature (20,21). This set of
experiments created the following groups:
control (n = 30), ANGII 10–9 (n = 10),
ANGII 10–8 (n = 11), ANGII 10–7 (n = 11),
ANGII 10–6 (n = 12), ANGII 10–5 (n = 12),
ANGII 10-4 (n = 12), ZD-7155 (n = 12), and
PD-123319 (n = 15). Furthermore, explants
were treated with ANGII at 10–9 mol/L in
the presence of ZD-7155 or PD-123319 at
10–5 mol/L, creating the additional
groups: ANG 10–9 + ZD-7155 (n = 12) and
ANG 10–9 + PD-123319 (n = 15). Cultures
were photographed daily and branching
morphogenesis was assessed according to
Nogueira-Silva et al. (22).
Western Blot Analysis
After 4 d in culture, lung explants
treated with ANGII at 10–9 mol/L, ZD-
7155 or PD-123319 were processed for
western blot analysis of nonphospory-
lated and phosporylated forms of mitogen-
activated protein kinases (MAPKs)
[p44/42, p38, JNK (mAbs; Cell Signaling
Technology, Danvers, MA, USA)] and
phosphatidylinositol-3-kinase (PI3K/Akt)
(Cell Signaling Technology) according to
Nogueira-Silva et al. (22). For loading
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control, blots were probed with β-tubulin
mAb (Abcam plc, Cambridge, UK) (n = 3).
Quantitative analysis was performed
with Quantity One 4.6.5 1-D Analysis
Software (Bio-Rad Laboratories, Her-
cules, CA, USA).
In Vivo Studies
Pregnant rats, control or exposed to ni-
trofen, were anesthetized at 12.5 dpc
with a mix of ketamine (75 mg/kg) and
medetomidine (0.5 mg/kg) for subcuta-
neous implantation of an osmotic micro-
pump filled either with saline or PD-
123319 (randomly), on mid scapular
region (Alzet osmotic pump Model
2ML1; Durect Corporation, Cupertino,
CA, USA). Saline or PD-123319 solution
was infused with a rate of 10 μL/h
(20 mg/kg/d for PD-123319). For the re-
versal of the sedative effect, atipamezole
(0.25 mg/kg) was used and butorfanole
(1 mg/kg) was administered immedi-
ately after the surgery. Fetuses were as-
signed to six experimental groups: Con-
trol rats treated with saline (C + S);
Control rats treated with PD-123319 (C +
PD); Nitrofen rats treated with saline 
(N + S); Nitrofen rats treated with PD-
123319 (N + PD); CDH rats treated with
saline (CDH + S); and CDH rats treated
with PD-123319 (CDH + PD).
Pregnant rats were randomly assigned
for cesarean section at 21.5 dpc or for
spontaneous delivery at term.
The pregnant rats killed at 21.5 dpc
were laparotomized, and after longitudi-
nal hysterotomy, each fetus (C + S, n =
14; C + PD, n = 15; N + S, n = 15; N + PD,
n = 12; CDH + S, n = 15; CDH + PD, n =
24) was extracted, weighed and decapi-
tated for organ harvesting (lungs, heart
and kidneys). Organs were also weighed
independently, organs-to-body weight
ratios were assessed and lungs were ei-
ther snap frozen in liquid nitrogen for
biochemical analyses or fixed in 4%
paraformaldehyde (PAF) for histological
analyses. In this set of experiments, the
level of lung hypoplasia was calculated
according to Baptista et al. (9).
The pups that were delivered sponta-
neously at term were placed immediately
after birth in a light-heated box and ran-
domly killed 5 min after birth or allowed
to survive, without any care, support
strategies or ventilatory support. Those
killed by decapitation at min 5 (C + S, n =
15; C + PD, n = 9; N + S, n = 11; N + PD,
n = 6; CDH + S, n = 12; CDH + PD, n =
14) were used for blood collection (neck
bleeding) and gasometric evaluation (i-
Stat1 analyser; Abbott, Chicago, IL, USA).
These were then dissected for identifica-
tion of CDH. Moreover, hearts were dis-
sected for right ventricular hypertrophy
evaluation and myocardial samples of
right ventricular free wall were harvested
and processed for q-PCR studies. The re-
maining fetuses were allowed to survive
(C + S, n = 10; C + PD, n = 9; N + S, n =
14; N + PD, n = 21; CDH + S, n = 14;
CDH + PD, n = 28), evaluated by two in-
dependent–blind observers (MJ Baptista
and S Nunes) and scored at 1, 3, 5 and
subsequently at each 5 min, using an
APGAR-like score (Table 1, adapted from
Dauger et al. [23]). The moment of death
was registered and defined by the mo-
ment in which the two observers attrib-
uted an APGAR 0 (marked cyanosis,
apnea, no spontaneous movements, no
response to stimulus). All experiments
were recorded in video to clarify any
doubt. These pups were opened post-
mortem for diaphragm inspection.
Lungs, heart and kidneys from all
pregnant rats were weighed for maternal
organ-to-body weight ratio analysis.
Biochemical Studies for Protein/DNA
Ratio Assessment
Total lungs (left and right) were
processed to determine protein and DNA
contents. Protein content was assessed
by Bradford method (24). DNA was ex-
tracted using the DNeasy Blood & Tissue
Kit (Qiagen, Hilden, Germany).
Histological Studies
The trachea was cannulated and the
lungs were fixed with PAF under a con-
stant pressure of 20 cmH2O. Lungs were
embedded in paraffin and 4-μm sections
were used to determine radial saccular
count [RSC; using hematoxilin-eosin
stain (H&E)], epithelial differentiation
[IHC for clara cell secretory protein
(CCSP) and prosurfactant protein C 
(SP-C) and determination of glycogen-
content using periodic acid-Schiff stain
(PAS)] and medial arterial thickness
(using Weigert stain).
RSC was estimated according to
Emery and Mithal adapted method (25),
at 100× magnification (Olympus BX61
microscope; Olympus, Tokyo, Japan), in
5 animals per group, 6 slides per animal
(200 μm apart each other), and 10 seg-
ments per slide, by a blinded examiner
(E Carvalho-Dias).
Regarding epithelial differentiation,
IHC was performed as previously de-
scribed by Nogueira-Silva et al. (7),
briefly described above. CCSP antibody
[07-623; Upstate (Millipore), Billerica,
MA, USA] was used in a 1:800 dilution
and SP-C antibody (AB3428; Chemicon
International, Temecula, CA, USA) in a
1:400 dilution. These slides and PAS
stained slides were observed and pho-
tographed (Olympus BX61 microscope).
The percentage of CCSP, SP-C and PAS
stained cells per microscopic field was
scored in a single-blinded fashion (100×
and 400× magnification, respectively) in
6 independent peripheral and 4 central
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Table 1. APGAR-like score.a
Sign Score 0 Score 1 Score 2
Skin color Marked cyanosis Mild cyanosis/ pale Pink
Breathing Apnea Irregular or weak breathing Regular breathing
Spontaneous motor No movements Weak movements Vigorous movements
activity
Reactivity to stimulus No response Gasping movements Active movements
aThis score is obtained by assigning a value (0, 1 or 2) to 4 characteristics: skin color, breathing,
spontaneous motor activity and reactivity to stimulus. The scores vary between 0 and 8.
areas per section (6 slides per animal,
200 μm apart each other, and 5 animals
per each experimental group). Scoring
was as follows: 1, 0–20% cells/field; 2,
20–40% cells/field; 3, 40–60% cells/field;
4, 60–80% cells/field; 5, 80–100%.
Weigert resorcin fuchsin solution
stains elastic fibbers, and it was used for
morphometric assessment of pulmonary
arteries (26). Pulmonary arteries were
distinguished from pulmonary veins on
the basis of the structure and position.
Arteries that were approximately round
[that is, the longest external diameter
(ED, distance between the external elastic
laminae), did not exceed the minimal ED
by more than 50%] and had both clearly
visible external and internal elastic lami-
nae were analyzed. As the structural
changes and pharmacological effects on
pulmonary arteries might be vessel size
dependent, we selected for further analy-
sis arteries subcategorized into 3 sizes:
ED less than 30 μm, ED 30 μm to 50 μm,
and ED greater than 50 μm. Then, using
AxionVision Rel. 4.3 (Carl Zeiss, Göttin-
gen, Germany), internal area (IA, defined
by internal elastic lamina), external area
(EA, defined by external elastic lamina)
and total area (TA, defined by edge of
the vascular sheath) were measured. The
percentage of medial (MA) and adventi-
tial arterial area (AA) were calculated ac-
cording to the following formulas: MA
(%) = [(EA – IA)/EA] × 100; AA (%) =
[(TA – EA)/EA] × 100. At least 10 arteries
for each section were evaluated, 6 sec-
tions per animal (200 μm apart each
other), and 3 animals per each experi-
mental group (at 400× magnification).
Right Ventricular Hypertrophy
Evaluation
Hearts (C + S, n = 8; CDH + S, n = 6;
CDH + PD, n = 8) were used for right
ventricle (RV) and left ventricle (LV) dis-
section (LV contains septum). RV and LV
were weighed separately. The ratio
RV/LV was determined and used as an
index of right ventricular hypertrophy.
Other hearts (C + S, n = 7; CDH + S, 
n = 6; CDH + PD, n = 6) were dissected,
transversally cut and orientated accord-
ing to short-axis view of the heart, before
fixed in PAF and embedded in paraffin.
Four micrometer sections were stained
with H&E and photographed at 40×
magnification (Olympus BX61 micro-
scope). The right ventricular wall thick-
ness was determined in the short-axis
view of the heart, in the maximum dis-
tance between the right side of the inter-
ventricular septum to the right ventricu-
lar free wall, using AxionVision Rel. 4.3
(Carl Zeiss) (5 measurements per animal,
20 μm apart each other).
q-PCR Studies
Right ventricular mRNA expression of
angiotensinogen, B-type natriuretic pep-
tide (BNP) and endothelin-1 (ET-1),
genes previously defined as ventricular
overload markers, was evaluated accord-
ing to Baptista et al. (27).
Statistical Analysis
Data are presented as mean ± SEM.
Statistical analysis was performed using
the statistical software SigmaStat (ver-
sion 3.5; Systat Software Inc., Chicago,
IL, USA). Multiple group comparisons
were made by analysis of variance. For
morphometric explants studies, Western
blot analysis, biochemical studies, histo-
logical studies, right ventricular hyper-
trophy evaluation and q-PCR studies,
one-way ANOVA on ranks was used.
Two-way ANOVA on ranks was used for
organ-to-body weight ratio analysis and
gasometric studies. Student-Newman-
Keuls test was used for posttest analysis.
Statistical significance was confirmed at
P < 0.05.
All supplementary materials are available
online at www.molmed.org.
RESULTS
RAS Components Expression Pattern
during Fetal Lung Development
The IHC studies revealed that all RAS
components, renin, ACE, angiotensino-
gen, AT1 and AT2 receptors, were ex-
pressed throughout all studied gesta-
tional ages in the fetal lung (Figure 1).
Renin was expressed in bronchiolar and
also in alveolar epithelium throughout
gestation (Figure 1A) since 13.5 dpc 
and appears to be maximal in the most
immature buds (see Supplemental Fig-
ures 1A-D). Endothelial ACE expression
started in larger proximal vessels, early
in the gestation, and spreads distally to
involve progressively smaller vessels
(Figure 1B). Interestingly, ACE protein
was also detectable in epithelial cells since
13.5 dpc (see Supplemental Figure 1E).
Regarding angiotensinogen, protein ex-
pression was clearly observed in epithe-
lial cells since 15.5 dpc (Figure 1C). Mes-
enchymal tissue also displayed scattered
angiotensinogen positive cells, first in
endothelial cells and in the later gesta-
tional ages (19.5 and 21.5 dpc) clearly in
vascular smooth muscle cells (Figure 1C).
AT1 receptor protein was first mainly ex-
pressed by undifferentiated mes-
enchyme at 15.5 dpc and, throughout
the gestation, it was predominantly ex-
pressed by vascular smooth muscle cells
and scattered in the mesenchyme (Fig-
ure 1D). AT2 receptor was expressed in
bronchial epithelial cells and since 19.5
dpc muscle cells of large blood vessels
also expressed it (Figure 1E). Moreover,
the epithelial AT2 expression was also
demonstrated at 13.5 dpc (see Supple-
mental Figure 1F).
Role of ANGII in Fetal Lung
Development
The presence of renin, ACE, angio -
tensinogen and AT1 and AT2 protein 
on lung during fetal development
prompted us to evaluate the role of
ANGII, the physiologically active pep-
tide of RAS, on lung morphogenesis. For
this purpose, fetal lung explants were
treated with increasing concentrations of
recombinant ANGII (Figure 2A). ANGII
significantly increased the number of pe-
ripheral airway buds, mainly with con-
centration of 10–9 mol/L, the minimal
concentration studied (Figure 2). On the
other hand, treatment of lung explants
with an AT1- antagonist (ZD-7155) signif-
icantly inhibited, whereas AT2-antago-
nist (PD-123319) treatment significantly
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enhanced lung branching in a similar
way to the dose of ANGII-inducing
maximal effect (Figure 2C). Moreover,
the stimulatory effect on lung branching
induced by ANGII 10–9 mol/L was com-
pletely abolished by AT1-antagonist
treatment, and the simultaneous lung
treatment with ANG 10–9 mol/L and PD-
123319 did not accomplish additional
stimulatory effect on explants growth
when compared with ANG 10–9 mol/L
treatment (Figure 2C). Thus, these re-
sults demonstrated that ANGII had a
stimulatory effect on lung branching,
mediated by AT1 receptor. Interestingly,
this stimulatory effect was mimicked by
treatment with AT2-antagonist alone.
To clarify the intracellular signaling
pathways that mediate ANGII actions on
lung growth, lung explants treated with
ANGII at 10–9 mol/L (selected due to its
maximal effect in explant growth), 
ZD-7155 or PD-123319 were evaluated
for MAPK and Akt pathways activation
(Figure 3A). AT1 receptor blockage in-
duced a significant decrease of p-38 and
JNK phosphorylation when compared
with control explants (Figures 3B, D, re-
spectively). On the other hand, the in-
crease on lung branching, induced by
ANGII at 10–9 mol/L and AT2 receptor
antagonist, significantly stimulated
p44/42 and Akt phosphorylation (Fig-
ures 3C, E, respectively).
In Vivo Antenatal PD-123319
Treatment Improves Fetal Lung Growth
Left, right and total lung-to-body
weight ratio (LW/BW) were analyzed
for different experimental groups. Ac-
cording to the nitrofen-induced CDH
experimental model, pups of nitrofen-
treated dams presented left and right
lung hypoplasia, which was maximal in
CDH + S group. Maternal PD-123319
treatment induced significant growth of
both left and right lungs in control,
 nitrofen and CDH groups. In fact,
LW/BW was significantly higher in the
control, nitrofen and also CDH rats
treated with PD-123319 when compared
with the respective saline-treated
groups (Figure 4A). Indeed, PD-123319
treatment stimulated partial recovery of
lung hypoplasia in CDH neonates, in-
ducing an increase of 11.4% in total lung
weight (Figure 4B). Considering these
results and to assess the potential of PD-
123319 as a useful treatment for severe
lung hypoplasia associated with CDH,
we pursued our study focused in com-
paring C + S, CDH + S and CDH + PD
groups.
Biochemical analysis of lung protein
and DNA content demonstrated that
there was no significant difference in
the protein/DNA ratio between C + S,
CDH + S and CDH + PD groups (C + S
0.024 ± 0.005; CDH + S 0.030 ± 0.004;
CDH + PD 0.026 ± 0.002).
The histological analysis of lung archi-
tecture showed that CDH + S lungs ap-
peared to have a thickened septal and
saccular walls and an increased amount
of interstitial tissue when compared with
C + S. However, CDH + PD had a signif-
icantly greater development of saccules
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Figure 1. Protein expression pattern of RAS components during fetal lung development
(from 15.5 until 21.5 dpc). (A) Renin was predominantly expressed in epithelium. (B) ACE
expression. (C) Angiotensinogen expression in epithelial, endothelial (arrow) and vascular
smooth muscle cells (arrowhead). (D) AT1 receptor immunostaining. (E) AT2 receptor im-
munostaining. Original magnification 200×.
and airspaces when compared with
CDH + S lungs (Figure 5A). In fact, RSC
of CDH + S pups was significantly lower
when compared with C + S group (Fig-
ure 5B). However, PD-123319 treatment
induced a significant increase on RSC of
CDH pups, that is, promoted distal lung
development (Figure 5B).
Regarding epithelial differentiation
and lung maturity, CCSP (proximal ep-
ithelial cell differentiation marker), SP-C
(distal epithelial cell differentiation
marker) and PAS+ glycogen stores (an in-
direct signal of immaturity) were evalu-
ated (Figure 6). No significant differences
in score of CCSP (Figure 6A), SP-C (Fig-
ure 6B) and PAS-stained cells (Figure 6C)
between C + S and CDH groups were
observed.
Concerning other organs than lungs,
nitrofen treatment (nitrofen and CDH
groups) induced decrease of heart-to-
body weight (HW/BW) and kidney-to-
body weight (KW/BW) ratios. However,
antenatal PD-123319 treatment did not
significantly change either HW/BW or
KW/BW (see Supplemental Figure 2).
Antenatal PD-123319 Treatment
Partially Reversed Arterial Structural
Abnormality and Decreased
Molecular Markers of PH on CDH
Model
MA percentage was significantly in-
creased in all arteries (independently of
its size) in CDH + S group when com-
pared with C + S and CDH + PD groups
(Figure 7). CDH + PD neonates pre-
sented a significant decrease in MA per-
centage when compared with CDH + S
for all arterial sizes, with maximal effect
on smaller arteries. The effect was so evi-
dent that CDH + PD arteries had no sig-
nificant difference in MA percentage
when compared with C + S group (Fig-
ure 7B). Regarding adventitial layer,
saline or PD-treated CDH groups pre-
sented a significant increase in AA per-
centage when compared with C + S for
all arterial sizes (Figure 7C). Thus, PD-
123319 treatment induced decrease of
MA percentage and did not induce any
change on AA percentage.
Regarding right ventricular hypertro-
phy index and right ventricle thickness,
markers of right ventricular hypertrophy
secondary to chronic PH, CDH neonates
did not present differences when com-
pared with control group. Moreover, PD-
123319 treatment did not change these
parameters (Table 2).
Additionally, expression levels of right
ventricular molecular markers of PH (an-
giotensinogen, BNP and ET-1) were as-
sessed in pups allowed to be delivered at
5 min after birth. In Figure 7D, mRNA
levels of these markers normalized to
β-actin are shown. CDH + S group pre-
sented a significant increase of angio -
tensinogen and an increase (although not
statistical significant) of BNP and ET-1
compared with C + S group. On its turn,
PD-123319 treatment significantly de-
creased these overload markers on CDH
pups.
Antenatal PD-123319 Treatment
Improves Lung Function and Survival
The adaptation of fetuses to extrauter-
ine life was monitored within the first
5 min after delivery by determining an
APGAR-like score (0-8). CDH + S
neonates presented an APGAR score of
2.35 ± 0.17, 1.82 ± 0.12 and 2.28 ± 0.18, at
1, 3 and 5 min after birth, respectively.
On the other hand, antenatal PD-123319
treatment improved APGAR score to
3.23 ± 0.26, 2.97 ± 0.09 and 2.71 ± 0.13, at
1, 3 and 5 min after birth (P < 0.05), re-
spectively.
Five minutes after birth, a moment in
which all neonates were alive, neonates
of C + S, N + S, CDH + S, N + PD and
CDH + PD groups were used for blood
collection (collected after decapitation)
and gasometric evaluation. When com-
pared with control pups, neonates of
 nitrofen-treated dams (N + S and 
CDH + S) presented significant acidosis,
decrease of PO2 and SatO2, and increase
of PCO2 and lactate, which was maximal
in CDH + S neonates (pups with maxi-
mal degree of lung hypoplasia) (Table 3).
On its turn, antenatal PD-123319 treat-
ment allowed a statistical significant in-
crease of pH, PO2 and SatO2, and de-
crease of PCO2 and lactate concentration.
Indeed, there was no difference in gaso-
6 |  N O G U E I R A - S I L V A E T  A L .  |  M O L  M E D  1 8 : X X - X X ,  2 0 1 2
P D - 1 2 3 3 1 9  A N D  C O N G E N I T A L  D I A P H R A G M A T I C  H E R N I A
Figure 2. Branching morphogenesis in a rat lung explant system. (A) Representative exam-
ples of control and fetal lung explants treated with ANGII at 10–9 mol/L, ZD-7155 (an AT1-
 antagonist) or PD-123319 (an AT2-antagonist). Original magnification 25×. (B) Number of
total airway buds of lung explants treated with increasing ANGII concentrations or (C) with
ZD-7155 (ZD), PD-123319 (PD), ANG 10–9 + ZD or ANG 10–9 + PD. Results are expressed as
ratio of d 4 (D4) and d 0 (D0) of culture (D4/D0 ratio). P < 0.05: *versus ANGII at 0 mol/L (con-
trol, C), §versus ANGII at 10–9 mol/L, †versus ZD-7155 at 10–5 mol/L, ‡versus ANG 10–9 + ZD.Q3
metric parameters between control, nitro-
fen, and CDH groups treated with PD-
123319 (Table 3).
Concerning neonatal survival, the aver-
age survival time was significantly longer
in PD-123319-treated pups than in CDH +
S pups (30.3 ± 3.2 min for CDH + S versus
42.4 ± 1.3 min for CDH + PD, P < 0.001).
As a result, all CDH + PD pups, but only
57% of the CDH + S pups, survived for
up to 30 min. At 45 min after birth, only
7% of CDH + S pups were alive, as op-
posed to over a third of CDH + PD pups.
In fact, PD-123319 treatment increased
survival rates of CDH neonates for all
time points evaluated (Figure 8).
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Figure 3. MAPK and Akt kinase activities in control (C) lung explants and treated with
ANGII at 10–9 mol/L (Ang 10–9), ZD-7155 (ZD) or PD-123319 (PD). (A) Western blot analysis
of p38, p44/42, JNK1/2 and Akt and to diphosphorylated forms of p38 (dp-p38), p44/42 
(dp-p44/42), SAPK/JNK (dp-JNK1/2) and Akt (dp-Akt). Control loading was performed
using β-tubulin (55 kDa). p38 corresponds to 38 kDa. p44/42 correspond to 44 and 42
kDa, respectively. JNK1 and 2 correspond to 46 and 54 kDa, respectively. Akt corre-
sponds to 56 kDa. Semi-quantitative analysis for dp-p38 (B), dp-p44/42 (C), dp-JNK1/2
(D), and dp-Akt (E). Results are presented as arbitrary units normalized for β-tubulin. P <
0.05: *versus ANGII at 0 mol/L (control, C), §versus ANGII at 10–9 mol/L, †versus ZD-7155 at
10–5 mol/L.
Figure 4. In vivo antenatal PD-123319
treatment effects on lung growth. (A) Ratio
of left, right and total lung-to-body weight
in control (C), nitrofen (N) and CDH groups
treated with saline (C + S, N + S, CDH + S)
or PD-123319 (C + PD, N + PD, CDH + PD).
Antenatal administration of PD-123319 en-
hanced lung growth in all studied groups.
(B) Effect of PD-123319 treatment on left,
right and total lung hypoplasia. Prenatal
administration of PD-123319 ameliorated
both left and right lung hypoplasia. Results
are expressed as %. P < 0.001: *versus C + S,
†versus N + S, ‡versus CDH + S, llversus C +
PD, §versus N + PD. For left lung, there is a
statistically significant interaction between
variables: disease*treatment (P = 0.009).
Regarding potential secondary effects
of PD-123319 on maternal organs, their
lungs, heart and kidneys were weighed.
PD-123319 treatment did not signifi-
cantly change maternal HW/BW,
KW/BW or LW/BW ratios (see Supple-
mental Figure 3).
DISCUSSION
This study demonstrated that all com-
ponents of RAS (renin, ACE, angio -
tensinogen, AT1 and AT2 receptors) were
constitutively expressed in the lung dur-
ing all studied gestational ages and that
ANGII had a stimulatory effect on lung
branching, mediated by AT1 receptor,
through p44/42 and Akt phosphoryla-
tion. This stimulatory effect on lung
growth was mimicked by treatment with
AT2-antagonist. Therefore, AT2 receptor
antagonist was evaluated as a putative
antenatal treatment for diseases charac-
terized by fetal lung hypoplasia such as
CDH. In an animal model of CDH, ante-
natal PD-123319 treatment increased neo-
natal lung growth, ameliorated indirect
parameters of PH, improved lung func-
tion and survival, without maternal or
fetal deleterious effects.
In past years, it has been demonstrated
that local ANGII formation and its
 tissue-specific effects on growth and dif-
ferentiation are thought to be extremely
important for embryonic and fetal devel-
opment (12). Regarding fetal lung, this
study corroborated previous evidences
concerning ACE, AT1 and AT2 expression
(13–15,28). For the first time, the present
study showed that renin and angio -
tensinogen are also expressed during
lung development. Interestingly, renin,
ACE and AT2 were expressed at very
early stages (since 13.5 dpc), suggesting
an important role for a local RAS since
early stages of lung development.
The results of RAS components expres-
sion prompted us to hypothesize that a
local RAS is active in the developing
lung. Therefore, the role of ANGII on
lung morphogenesis was evaluated.
ANGII supplementation induced an in-
crease in lung explants growth, and it is
necessary to stress that this enhancing ef-
fect of ANGII on number of peripheral
airways buds of lung reached about 37%,
whereas the stimulatory effect induced
by fibroblast growth factor-10 (FGF-10), a
classical and very important lung growth
factor, in a similar model of murine lung
explants, was around 20% (29). The pos-
sible mechanism by which RAS inter-
feres with the airway branching or pul-
monary vascular development is still
unclear, and further investigation is re-
quired. However, it was already substan-
tially demonstrated that reciprocal inter-
actions between airways and blood
vessels are critical for normal lung devel-
opment. For instance, it was demon-
strated that ablation of lung epithelium
impair lung vascular cells development
(30). Moreover, VEGF inhibition in neo-
natal rats leads to arrested alveolar de-
velopment, suggesting that inhibition of
vascular growth itself may directly im-
pair lung development (31–33). Thus,
given that, in the present study, it was
demonstrated that some components of
RAS are expressed on epithelium and
others on mesenchyme/vascular cells, it
is possible that RAS is involved in both
processes: airway and vasculature
branching.
Interestingly, AT1 receptor inhibitor de-
creased, whereas AT2-antagonist signifi-
cantly increased lung growth in explants.
This opposite effect of AT1 and AT2 re-
ceptors, namely a stimulatory effect of
AT1 and inhibitory effect of AT2, is also
described on other tissues (34–39).
Many of the effectors that modulate
fetal lung branching seem to activate
MAPK and/or PI3K/Akt cascades (40).
Thus, MAPK and PI3K/Akt pathway ac-
tivation by ANGII and AT1 and AT2 an-
tagonists in fetal lung development was
investigated. ANGII and AT2 receptor an-
tagonist treatment induced an increase in
lung branching by the stimulation of
p44/42 and Akt phosphorylation. These
intracellular mediators are also involved
in AT1 effects on proliferation and sur-
vival of cells in other tissues (34,37). Re-
garding lung growth inhibition induced
by AT1 antagonist, it was mediated by a
decrease of p-38 and JNK phosphoryla-
tion. These MAPK families were already
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Figure 5. Antenatal PD-123319 treatment increased RSC. (A) Representative H&E stained
sections of C + S, CDH + S and CDH + PD lungs, used to RSC analyzes. Note greater sac-
cular development and increase of lung aeration in CDH + PD compared with CDH + S.
Original magnification 100×. (B) Mean radial saccular count in C + S, CDH + S and CDH +
PD groups. PD-123319 treatment induced increase of RSC in CDH pups. P < 0.001: *versus
C + S, ‡versus CDH + S.
demonstrated to be involved on induc-
tion of lung branching (22).
The in vitro studies demonstrated that
a local RAS is functional at early stages
of lung morphogenesis. Moreover, the
significant stimulatory effect on lung
growth mediated by AT2 receptor antag-
onist led us to hypothesize that AT2
could be a new target for treatment of
diseases characterized by fetal lung hy-
poplasia, such as CDH. In fact, AT2 re-
ceptor is described to be expressed virtu-
ally only during fetal life (11,12,41),
which would annul potential maternal
adverse effects. Thus, treatment with AT2
antagonist (PD-123319) was selected for
the in vivo study, in which the nitrofen-
induced CDH rat model (19,42) was
used. The gestational age selected for
maternal PD-123319 administration was
based on the effect observed on lung ex-
plants that were harvested at 13.5 dpc.
The nitrofen-induced CDH model is an
experimental model of severe lung hy-
poplasia, which reasonably replicates the
major abnormalities and the pathophysi-
ology described in human CDH (42–44).
Although the mechanism by which nitro-
fen induces the diaphragmatic defect and
lung hypoplasia is not fully understood,
recent evidences suggest the involve-
ment of abnormalities linked with the
retinoid signaling pathway in this model
and also in human CDH etiology
(42–45). Indeed, one clinical study
demonstrated the presence of decreased
levels of retinol and retinol-binding pro-
tein in human CDH, suggesting a possi-
ble deterioration of retinol transport
across the placenta (46). Regarding the
nitrofen-induced CDH model, it was al-
ready demonstrated that nitrofen inhibits
retinal dehydrogenase 2 (RALDH2), a
key enzyme responsible for the conver-
sion of retinal to retinoic acid (47). More-
over, the co-administration of retinoids
(Vitamin A or retinoic acid) in nitrofen-
induced CDH induces lung growth and
reduces the incidence of CDH (9,10,48).
Interestingly, some studies have de-
scribed an inhibitory interaction between
retinoid acid pathway and RAS, namely
in adult cardiac remodeling (49,50).
Thus, a possible interaction between
retinoid acid pathway and RAS might 
be present during lung morphogenesis,
but the underlying mechanisms remain
unclear and further investigation is 
required.
Maternal PD-123319 subcutaneous ad-
ministration significantly increased lung
growth in control, nitrofen and CDH
groups. In fact, in CDH neonates, despite
the presence of mechanical forces that
compress lungs, PD-123319 induced par-
tial recovery of lung hypoplasia as as-
sessed by LW/BW (an increase of 11.4%).
In face of these results and to assess if
the treated-lung is structural and func-
tionally ameliorated, we focused further
studies in comparing C + S, CDH + S
and CDH + PD groups. In human and
experimental CDH there is a reduction in
peripheral lung development (1,10). PD-
123319 treatment stimulated lung growth
by promoting distal lung development as
measured by the enhanced RSC. The po-
tential clinical relevance of this effect
should be emphasized, since such an in-
crease in lung parenchyma can be deter-
minant in providing a better adaptation
of CDH fetus to extrauterine life.
Regarding epithelial differentiation
and lung maturity, CCSP (a Clara cells
marker, marker for proximal lung), SP-C
(a type II pneumocytes marker, marker
for distal lung) and PAS glycogen stores
(a signal of immaturity) were assessed.
No differences between groups were de-
tected in CCSP, SP-C and PAS-stained
cells score. Contradictory results about
lung maturity and surfactant status in
CDH animal models have been pub-
lished, with studies demonstrating that
the CDH lung is surfactant deficient
(51–53) and others indicating no change
in alveolar surfactant composition, un-
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Figure 6. Antenatal PD-123319 treatment did not interfere with epithelial differentiation
and lung maturation. (A) Representative CCSP-stained sections of C + S, CDH + S and
CDH + PD lungs. Original magnification 100×. (B) Score of CCSP-stained cells in C + S,
CDH + S and CDH + PD groups. (C) Representative SP-C stained sections in different
groups. Original magnification 200×. (D) Score of SP-C-stained cells. (E) Representative PAS
stained sections of C + S, CDH + S and CDH + PD lungs. Original magnification 400×. Ar-
rows: PAS+ (glycogen-rich) cells. (F) Score of PAS-stained cells. No significant difference be-
tween experimental groups was observed in CCSP, SP-C and PAS.
changed or even increased surfactant
protein expression (54–57). However,
one of the most recent studies per-
formed with human CDH fetuses
demonstrated that surfactant maturation
is not delayed (54). The present study
corroborates the idea that CDH does not
appear to interfere or delay epithelial
differentiation and surfactant accumula-
tion (54). Moreover, PD-123319 treat-
ment did not impair fetal lung matura-
tion in CDH neonates.
Persistent PH accounts for significant
mortality and morbidity in CDH
(1,2,58). In severe human CDH and also
in nitrofen-induced model of CDH, it
was already demonstrated that PH re-
sults from decreased number of arteries,
increased thickness of media and ad-
ventitia of pulmonary arterial walls and
distal muscular extension to the non-
muscular intra-acinar arteries (58,59). In
this study, the effect of PD-123319 treat-
ment on PH was indirectly assessed by
morphometric pulmonary vascular anal-
ysis (59) and its cardiac repercussion by
determination of right ventricular hy-
pertrophy index and right ventricle
thickness, and quantification of right
ventricular overload molecular markers
(Angiotensinogen, BNP and ET-1) (27).
To better analyze the vessel morphol-
ogy, areas were measured instead of
thickness since this approach avoids the
bias introduced by irregular shape of
elastic laminae. Thus, PD-123319 treat-
ment induced decrease of MA percent-
age for all arterial sizes, with maximal
effect on smaller arteries. Moreover,
CDH + S neonates did not present dif-
ferences in right ventricular hypertro-
phy index and right ventricular wall
thickness (morphological markers)
when compared with C + S group, but
they presented an increase of molecular
markers of right ventricular overload.
Thus, 5 min after birth, CDH + S
neonates only presented molecular
changes secondary to PH, but not yet
morphological alterations (secondary to
chronic PH). PD-123319-treated CDH
pups presented a significantly decrease
of right ventricular overload molecular
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Figure 7. Indirect pulmonary hypertension assessment. (A) In upper panel are presented
representative examples of pulmonary arteries > 50 μm stained with Weigert resorcin
fuchsin solution of C + S, CDH + S and CDH + PD groups; in lower panel, representative
examples of small pulmonary vessels (<30 μm) for each group are presented. Original
magnification 400×. (B) Percentage medial area of pulmonary arteries of different exter-
nal diameters. (C) Percentage adventitial area of pulmonary arteries of different exter-
nal diameters. (D) Right ventricular levels of angiotensinogen, BNP and ET-1 mRNA in 
C + S, CDH + S and CDH + PD neonates, expressed in arbitrary units normalized for 
β-actin. PD-123319 treatment significantly decreased arterial medial area and these
overload markers on CDH pups. P < 0.001: *versus C + S, ‡versus CDH + S. , C + S; 
, CDH + S; , CDH + PD.
markers and did not influence morpho-
logical markers. Therefore, PD-123319
maternal administration partially re-
versed pulmonary arterial structural ab-
normality that characterizes CDH and
decreased molecular markers of PH,
which suggest that PD-123319 might re-
duce pulmonary vascular reactivity, and
the risk of postnatal persistent PH ob-
served in CDH neonates.
Regarding other antenatal pharmaco-
logical strategies to decrease PH in
CDH, Luong et al. demonstrated recently
that antenatal sildenafil treatment (from
11.5 to 20.5 dpc, daily subcutaneous in-
jection) attenuates PH in experimental
CDH (3). In fact, that study demon-
strated that antenatal sildenafil treat-
ment improved lung structure, increased
pulmonary vessel density and reduced
right ventricular hypertrophy in CDH
(3). However, in opposition to PD-
123319 treatment, sildenafil had not pro-
moted lung growth, as demonstrated by
LW/BW, and consequently it did not in-
duce a recover of lung hypoplasia (3).
Moreover, it is necessary to stress that
the idea that there is PH in CDH, since
fetal period, is underlying to Luong’s
study (3). Nonetheless, it was already
demonstrated that there is vascular hy-
poplasia in nitrofen-induced CDH and
neonatal PH, but it is not yet proven the
presence of PH in CDH fetus (27,58,59).
Indeed, immediately after the birth,
Luong et al. demonstrated the presence
of right ventricular hypertrophy (an in-
direct signal of PH) in CDH neonates
(3). In the present study, CDH neonates
at 5 min after the birth did not present
increase of right ventricular hypertrophy
index or right ventricle thickness. How-
ever, CDH + S neonates presented an in-
crease of right ventricular overload
markers which reveals a molecular car-
diac repercussion. According to the liter-
ature, it was already demonstrated that
CDH vascular pulmonary alterations
only affect neonatal and not fetal hemo-
dynamics. Baptista et al. demonstrated
that CDH is associated with significant
molecular alterations secondary to PH,
but only in the right ventricle and after
birth (27). Moreover, also in fetal lamb
CDH model, it was demonstrated that
newborn CDH lambs had no differences
in right ventricular weight or right ven-
tricular wall thicknesses compared with
control lambs (60). Thus, despite the oc-
currence of pulmonary vascular modifi-
cations from early stages of prenatal de-
velopment, the present study also shows
that PH is only present after birth, likely
occurring secondary to vascular hy-
poplasia that characterizes CDH, and
also consequently to pulmonary vaso-
constriction, which is secondary to alve-
olar hypoplasia, hypoxia and acidosis.
So, antenatal PD-123319 treatment in-
terfered and improved the key determi-
nants of mortality associated with CDH,
namely lung hypoplasia and PH. Fur-
thermore, maternal PD-123319 adminis-
tration improved lung function, namely
pulmonary gas exchange, as demon-
strated by APGAR score, gasometric
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Figure 8. Survival analysis. (A) Representa-
tive examples of cyanotic color of CDH + S
versus pink coloration of CDH + PD
neonates at 5 min of life. (B) Survival rates
(expressed as percentage of pups surviving
at each 5 min) of CDH + S and CDH + PD
neonates. Antenatal PD-123319 treatment
improved survival time in CDH pups (mean
survival time: CDH + S 30.3 ± 3.2 min; CDH +
PD 42.4 ± 1.3 min, P < 0.001). , CDH + S; 
, CDH + PD.
Table 2. Right ventricular hypertrophy evaluation 5 min after birth.a
Ratio of right/left ventricular weight Right ventricular wall thickness (μm)
C + S 0.49 ± 0.08 214.02 ± 9.29
CDH + S 0.44 ± 0.05 200.59 ± 4.27
CDH + PD 0.52 ± 0.05 220.31 ± 12.26
C, control; CDH, congenital diaphragmatic hernia; PD, PD-123319; S, saline.
aValues represent the mean ± SEM of measurements. P < .05: No significant difference
between experimental groups was observed.
Table 3. Neonatal blood gasometric evaluation 5 min after birth.a
pH PCO2 (mmHg) PO2 (mmHg) SatO2 (%) Lactate (mmol/L)
C + S 7.30 ± 0.03 22.69 ± 2.33 102.80 ± 7.78 93.60 ± 2.50 6.83 ± 0.39
N + S 6.94 ± 0.03b 38.49 ± 3.21b 62.50 ± 5.36b 67.25 ± 5.58b 8.50 ± 0.51b
CDH + S 6.92 ± 0.02b 51.05 ± 1.71bc 52.00 ± 6.06b 58.50 ± 7.06b 9.56 ± 0.57b
N + PD 7.18 ± 0.08c 23.62 ± 3.39c 95.67 ± 6.49c 90.83 ± 2.44c 6.88 ± 0.82c
CDH + PD 7.03 ± 0.04de 24.63 ± 5.83d 95.00 ± 8.20d 87.80 ± 3.65d 6.73 ± 0.70d
C, control; CDH, congenital diaphragmatic hernia; N, nitrofen; PD, PD-123319; PCO2, CO2
partial pressure; PO2, O2 partial pressure; S, saline; SatO2, O2 saturation. 
aValues represent the mean ± SEM of measurements.
bP < 0.05 versus C + S; cversus N + S; dversus CDH + S; eversus N + PD. There is a statistically
significant interaction between variables: disease*treatment for pH, PCO2, PO2 and SatO2.
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and survival evaluation. Regarding gas-
ometry it is necessary to stress that due
to low fetal blood volume, all blood
possibly collected by decapitation was
used for gasometric evaluation. So, gas-
ometry evaluated a mix of arterial and
venous blood. Nonetheless, antenatal
PD-123319 treatment allowed a statisti-
cal significant improvement of acidosis,
hypercapnia, hypoxia and lactate con-
centration that characterizes CDH fe-
tuses. The results of these direct indica-
tors of ventilation/perfusion matching
quality suggest an obvious improve-
ment of pulmonary gas exchange and
peripheral O2 delivery. Furthermore,
this enhancement on lung function had
important consequences on neonatal
survival, namely PD-123319 treatment
induced significantly longer average
survival time. However, it is necessary
to stress that the survival evaluation
was performed without neonatal care or
ventilatory support. This fact might be
the explanation for the death of all
neonates, despite the increase on lung
function and survival time induced by
antenatal PD-123319 treatment.
Regarding potential fetal adverse ef-
fects, the nitrofen-exposed pups pre-
sented decrease of HW/BW and
KW/BW ratios as previously docu-
mented (10,61–63). On the other hand,
PD-123319 beneficial effect seemed lung-
specific, since HW/BW and KW/BW ra-
tios of the pups were not altered. Con-
cerning potential maternal secondary
effects induced by PD-123319, no differ-
ences on heart, kidneys and lungs were
observed. The absence of maternal dele-
terious effects could be due to the fact of
AT2 receptor expression is dramatically
decreased after birth, being restricted to
a few organs (11,12,41). Indeed, an in-
crease of AT2 receptor expression during
adult life has been only observed under
pathological conditions (41).
CONCLUSION
In conclusion, this study demonstrated
the existence of a functional local RAS in
fetal lung. Moreover, it establishes AT2
receptor antagonist (PD-123319) as a pu-
tative antenatal therapy for pathologies
characterized by fetal lung hypoplasia,
such as CDH.
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